[{"arm_notes": "", "treatment_id": null, "treatment_name": "Experimental Group: FINLAY-FR-2 25 ug RBD-TT; Intramuscular route (IM); 0.5 mL; 0 - 28 days + FINLAY-FR-1A (50 ug d-RBD+ alumina; IM; 0.5 mL) as booster dose 56 day. FINLAY-FR-2 Presentation: Vial with single dose and vial multidoses FINLAY-FR-1A Presentation: Vial with single dose and vial multidoses;Immunogenicity; Vaccine", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "25 \u00b5g+50 \u00b5g;2+1;Days0-28+day56", "treatment_id": 1519, "treatment_name": "Finlay-fr-1a anti-sars-cov-2 vaccine+finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]